“2015 was a transformational year for Pfizer. We achieved operational revenue growth and have a solid portfolio of market-leading products and a healthy R&D pipeline. We completed the Hospira acquisition and strengthened the future potential of the company through the proposed Pfizer-Allergan combination.”

— Ian Read, Chairman and CEO

$49B
In revenues in 2015

7
Products with sales greater than $1B in 2015

64
Manufacturing sites worldwide
SCIENTIFIC INNOVATION

ADVANCES IN ONCOLOGY
Our scientists are hard at work seeking to turn promising research into potentially important medicines and making strides in innovative fields such as immuno-oncology as we build a pipeline of potential next-generation therapies so people with cancer may live longer, fuller lives. By bringing potentially life-changing therapies and support to patients, we aim to redefine life with cancer until we cure it. Stories include: Redefining Life with Cancer; and, Immuno-Oncology — Broad Portfolio of Assets in Clinical Development.

BROADENING THE VACCINES PORTFOLIO
Leveraging leading technology in vaccine design and conjugation, we are pursuing preventative solutions to complex, difficult-to-treat bacterial pathogens — across the lifespan. We are also exploring the power of novel therapeutic vaccines to treat chronic conditions and diseases such as cancer. Stories include: Taking on Meningococcal Meningitis; Investigational Vaccines Advancing in Pipeline; and, Maternal Vaccination.
PARTNERSHIPS

**PEER COLLABORATIONS**
Collaborating in new and dynamic ways with innovators across the health landscape is very important in our efforts to improve patients’ lives. Increasingly, this has led to unique, focused alliances with our global pharmaceutical peers. Stories include: Breaking Through with Merck KGaA, Darmstadt, Germany; Developing Next-Generation Manufacturing: Portable, Continuous, Miniature and Modular; In Phase 3 with Eli Lilly; Project Data Sphere Collaboration in Oncology; Next-Generation Sequencing-Based Companion Diagnostics Collaboration; GO AIM Conference Convenes Cancer Patient Advocates and Industry; and, Supporting the Dementia Discovery Fund.

**RESEARCH COLLABORATIONS**
Our research partners include academic institutions, foundations, government institutions, other biopharmaceutical companies and physicians — expanding the R&D ecosystem to better serve the needs of patients. Stories include: Pfizer’s Centers for Therapeutic Innovation; Creative Collaboration That Preserves the Culture of our Biotech Partners; and, accounts of partnerships with Spark Therapeutics, Inc., 23andMe, Inc. and AARP.®

**PARTNERING TO EXPAND ACCESS**
At Pfizer, we believe that all individuals deserve access to quality health care and the opportunity to lead healthy lives. We combine traditional philanthropic methods with novel approaches that create an enduring and meaningful impact on public health systems to facilitate access to health care for underserved communities around the world. Stories include: Gavi, the Vaccine Alliance; and, Sayana® Press and Family Planning.
HUMAN HEALTH IMPACT

GLOBAL REACH
Everywhere we work and live, Pfizer is a vital force for improving people’s lives through the business of life science — fostering human health and well-being in multi-faceted countries and unique markets around the world. Countries profiled include China, India, Mexico, South Africa and the United Kingdom.

THE GLOBAL GOALS
The United Nations has adopted 17 Global Goals for sustainable development. At Pfizer, we believe that good health is fundamental to advancing all of them. Stories include: Embracing the 2030 Sustainable Development Goals; and, Health, the Goal That Underlies All.

ENVIRONMENT
At Pfizer, we continue to work for a sustainable future, recognizing that embedding environmental sustainability into our business can bring significant value to our company, the people who use our products and the communities we touch. Stories include: Progress on Our 2020 Environmental Sustainability Goals; Our Green Journey; and, Pfizer Issues Supply Chain Environmental Sustainability Goal.
MANUFACTURING AND SUPPLY CHAIN

Footprint and Capabilities Grow with Hospira Acquisition

The Hospira acquisition enhances our ability to address global demand for specialized medicines, adding global talent and significant global manufacturing infrastructure — 11 biopharma manufacturing sites including two of the largest and most advanced sterile injectable manufacturing facilities in the world. The integration also adds two facilities for the manufacture of proprietary IV sets and infusion pumps to support the Infusion Systems business.

COLLEAGUES

With OWNIT! we continue to build a culture that positions Pfizer for long-term success. Stories include: A Winning Combination of Cultures; Driving Inclusion through Colleague Engagement; Pfizer Reaches One Million Followers on LinkedIn; Colleagues “Dare to Try” to Spur Growth; and, Colleague Health and Safety.

97,000*

MORE THAN 97,000 COLLEAGUES AROUND THE WORLD

*As of December 31, 2015